MDXXF (Pharmala Biotech Holdings) Total Liabilities: $0.71 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.11
GF Value $0.15
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Total Liabilities?

Pharmala Biotech Holdings MDXXF 33 Total Liabilities is $0.71 Mil as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.15 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Pharmala Biotech Holdings's Total Liabilities for the quarter that ended in Feb. 2026 was $0.71 Mil.

Pharmala Biotech Holdings's quarterly Total Liabilities increased from Aug. 2025 ($0.70 Mil) to Nov. 2025 ($0.73 Mil) but then declined from Nov. 2025 ($0.73 Mil) to Feb. 2026 ($0.71 Mil).

Pharmala Biotech Holdings's annual Total Liabilities declined from Aug. 2023 ($0.76 Mil) to Aug. 2024 ($0.67 Mil) but then increased from Aug. 2024 ($0.67 Mil) to Aug. 2025 ($0.70 Mil).

Pharmala Biotech Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Total Liabilities Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Liabilities
0.11 0.33 0.76 0.67 0.70

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.63 0.70 0.73 0.71
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharmala Biotech Holdings's Total Liabilities for the fiscal year that ended in Aug. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.697+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.70

Total Liabilities=Total Assets (A: Aug. 2025 )-Total Equity (A: Aug. 2025 )
=2.479-1.782
=0.70

Pharmala Biotech Holdings's Total Liabilities for the quarter that ended in Feb. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.713+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.71

Total Liabilities=Total Assets (Q: Feb. 2026 )-Total Equity (Q: Feb. 2026 )
=2.293-1.58
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.71 Mil mean?
Pharmala Biotech Holdings (MDXXF) has a Total Liabilities of $0.71 Mil as of Feb. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Total Liabilities too high?
Pharmala Biotech Holdings' current Total Liabilities is $0.71 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Total Liabilities compare to VRTX and REGN?
Pharmala Biotech Holdings' Total Liabilities of $0.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Total Liabilities is $0.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 29.5% below its estimated fair value. The current Total Liabilities is $0.71 Mil. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Total Liabilities is $0.71 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 29.5% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Significantly Undervalued.

Key valuation signals for MDXXF:

  • Total Liabilities: $0.71 Mil
  • GF Value™: $0.15 vs. price of $0.11 (29.5% below fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value